Compare Amgen, Inc. (AMGN) vs Newegg Commerce Inc (NEGG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Newegg Commerce Inc — how do they compare? Amgen, Inc. trades at $362.14 (market cap $196.12B), while Newegg Commerce Inc trades at $14.15 (market cap $300.34M). The key difference: Amgen, Inc. is far larger — about 653× Newegg Commerce Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while Newegg Commerce Inc pays none. Which is the better fit depends on your goals.
| AMGN | NEGG | |
|---|---|---|
Market Cap | $196.12B | $300.34M |
Sector | Health | Consumer Cyclical |
52-Week High | $388.16 | $128.09 |
52-Week Low | $271.18 | $14.15 |
Enterprise Value | $241.41B | $299.14M |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
NEGG trades at $14.15, down 4.2% today, with a bearish technical signal from moving averages but oversold RSI readings. The company reported a net loss of $4.88M in 2025, though revenue was $1.44B and the net margin improved to -0.34%. Recent news highlights AI shopping features and sales events, while cash flow trends show operational challenges but financing support.
The outlook remains cautious; while valuation ratios like P/S of 0.21 appear low, profitability is weak and cash burn persists. Risks include competitive pressures and execution hurdles, but a sole analyst rates it Buy. Investors should weigh cost controls against sustained losses before considering a position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Newegg Commerce Inc
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home and gaming products and provides certain third-party logistics services globally.
Read more on NEGG →
